I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademark Office on November 12, 2007.

COMMUNICATION Patent Application Docket No. G-175US03PCT

Frank C. Eisenschenk, Ph.D., Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner

David Lukton, Ph.D.

Art Unit

1654

Applicants

Kristen Briggs, Deno Dialynas, John Lucas, Aaron Scalia

Serial No.

10/510,002

Filed

September 29, 2004

Conf. No.

7745

For

XCRF Polynucleotides and Polypeptides and Uses Thereof

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313

COMMUNICATION

Sir:

Applicants received a Restriction Requirement dated October 12, 2007 in the aboveidentified patent application. The Disposition of Claims on the Office Action Summary page indicates that claims 16-26 are pending. In addition, page 2 of the Restriction Requirement indicates that claims 1-15 have been cancelled and claim 16-26 added by Applicants' Preliminary Amendment. However, Applicants respectfully assert that claims 1-14 were canceled and claims 15-34 were added in the Preliminary Amendment dated September 29, 2004. The issuance of a new Restriction Requirement is respectfully requested taking into account all the pending claims.

Respectfully submitted,

Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.:

352-375-8100

Fax No.:

352-372-5800

Address:

P.O. Box 142950

Gainesville, FL 32614-2950

FCE/sl